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Summary
Background Patterns of health-care use and comorbidities present in patients in the period before diagnosis of chronic 
obstructive pulmonary disease (COPD) are unknown. We investigated these factors to inform future case-ﬁ nding 
strategies.
Methods We did a retrospective analysis of a clinical cohort in the UK with data from Jan 1, 1990 to Dec 31, 2009 
(General Practice Research Database and Optimum Patient Care Research Database). We assessed patients aged 
40 years or older who had an electronically coded diagnosis of COPD in their primary care records and had a 
minimum of 3 years of continuous practice data for COPD (2 years before diagnosis up to a maximum of 20 years, 
and 1 year after diagnosis) and at least two prescriptions for COPD since diagnosis. We identiﬁ ed missed opportunites 
to diagnose COPD from routinely collected patient data by reviewing patterns of health-care use and comorbidities 
present before diagnosis. We assessed patterns of health-care use in terms of lower respiratory consultations (infective 
and non-infective), lower respiratory consultations with a course of antibiotics or oral steroids, and chest radiography. 
If these events did not lead to a diagnosis of COPD, they were deemed to be missed opportunities. This study is 
registered with ClinicalTrials.gov, number NCT01655667.
Findings We assessed data for 38 859 patients. Opportunities for diagnosis were missed in 32 900 (85%) of 
38 859 patients in the 5 years immediately preceding diagnosis of COPD; in 12 856 (58%) of 22 286 in the 6–10 years 
before diagnosis, in 3943 (42%) of 9351 in the 11–15 years before diagnosis; and in 95 (8%) of 1167 in the 16–20 years 
before diagnosis. Between 1990 and 2009, we noted decreases in the age at diagnosis (0·05 years of age per year, 
95% CI 0·03–0·07) and yearly frequency of lower respiratory prescribing consultations (rate ratio 0·982 opportunities 
per year, 95% CI 0·979–0·985). Prevalence of all comorbidities present at COPD diagnosis increased except for 
asthma and bronchiectasis, which decreased between 1990 and 2007, from 281 (33·4%) of 842 patients to 
451 of 1465 (30·8%) for asthma, and from 53 of 842 (6·3%) to 53 of 1465 (3·6%) for bronchiectasis. In the 2 years 
before diagnosis, of 6897 patients who had had a chest radiography, only 2296 (33%) also had spirometry.
Interpretation Opportunities to diagnose COPD at an earlier stage are being missed, and could be improved by case-
ﬁ nding in patients with lower respiratory tract symptoms and concordant long-term comorbidities.
Funding UK Department of Health, Research in Real Life.
Introduction
Chronic obstructive pulmonary disease (COPD) is a 
progressive, destructive disease of the airways and lung 
parenchyma with no clear pathological or clinical starting 
points. The insidious and progressive nature of the 
disease can result in severe, irreversible damage by the 
time symptoms present and a diagnosis is made.1 The 
earlier the diagnosis of COPD is made, the greater the 
potential to reduce damage to the lungs2,3 through 
addressing lifestyle factors such as smoking and lack of 
physical activity,4 and the prevention of COPD 
exacerbations, which are associated with disease 
progression. The National Outcomes Strategy for COPD, 
published by the UK Department of Health, provides a 
framework for improving outcomes of COPD in 
England.5 The Strategy estimated that 835 000 people 
have a diagnosis of COPD, with a further 2·2 million 
people living with undiagnosed COPD.5 Early COPD 
diagnosis followed by appropriate intervention has the 
potential to save the UK National Health Service more 
than £1 billion over 10 years.6
The onset of signs of lung disease should prompt 
appropriate investigations, such as spirometry. 
However, both patients and doctors often fail to 
recognise the signiﬁ cance of symptoms.5 In addition, 
some patients (particularly men) are reluctant or slow 
to express concern and seek advice.7 A holistic disease 
management approach—in which all present and 
potential comorbidities are assessed—has been 
suggested as an approach to evaluate those at risk of 
developing COPD.5 Compared with control populations 
without this disease, patient populations with COPD 
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have higher prevalence of cardiovascular disease, 
diabetes, peptic ulcer, gastro-oesophageal reﬂ ux 
disease, and lung cancer.8–12 Shared risk factors 
between comorbidities, including lifestyle (eg, cigarette 
smoking), environmental and occupational exposures, 
and airway or generalised chronic inﬂ ammation from 
other causes all contribute to chronic ill-health and 
inactivity. These factors promote a cycle of debility, 
muscle wasting, increased susceptibility to COPD 
exacerbations, and worsening comorbidities.13,14 Al-
though comorbidities are common, guidelines and 
governmental initiatives to improve management of 
chronic disease are usually disease-speciﬁ c.
COPD exacerbations accelerate worsening of lung 
function, leading to: quicker disease progression,15 
reduced mobility,16 and poorer quality of life.3,17 Indeed, 
COPD exacerbations account for a large proportion of 
the COPD-associated costs in primary and secondary 
care.18 Identiﬁ cation of people with as yet undiagnosed 
COPD, using a case-ﬁ nding approach19 might facilitate 
earlier intervention to prevent exacerbations and slow the 
decline of lung function.3
Major guidelines and strategic statements assert that 
early diagnosis, combined with eﬀ ective interventions, can 
reduce the health burden and ﬁ nancial cost of symptomatic 
COPD.1,20,21 However, the precise mechanisms through 
which this can be achieved are not yet agreed.1,20,22 In this 
study we assessed patterns of health-care use and 
comorbidities before a diagnosis of COPD to inform future 
case-ﬁ nding strategies.
Methods
Study design and dataset
We did this retrospective, cohort study with primary and 
secondary care data routinely collected between Jan 1, 
1990, and Dec 31, 2009, in the UK. Data were pooled 
from the General Practice Research Database, part of the 
Clinical Practice Research Datalink21,23 and the Optimum 
Patient Care Research Database.24 The Optimum Patient 
Care Research Database has been approved for clinical 
research use by the Trent Multi Centre Research Ethics 
Committee.24 The study protocol was approved by the 
General Practice Research Database’s independent 
scientiﬁ c advisory committee and the Optimum Patient 
Care Research Database’s anonymised data ethics and 
transparency committee.
Eligible patients were aged 40 years or older with an 
electronically coded diagnosis of COPD in their primary 
care records between 1990 and 2009. The minimum age 
was chosen because COPD predominantly aﬀ ects people 
aged 40 years and older.25 All patients had a minimum of 
3 years of continuous practice data (up to a maximum of 
20 years), 2 years before diagnosis and 1 year after 
diagnosis, and at least two prescriptions for COPD-
related drugs since diagnosis. This criterion indicates 
continued treatment and was used as a proxy for 
diagnosis of symptomatic disease.22
Procedures
We reviewed data for a maximum of 20 years before 
diagnosis, including demographic characteristics, data 
about use of health-care resources indicative of missed 
opportunities for diagnosis, and comorbidities. This 
40-year period (1970–2009) coincided with the migration 
of patient records from a paper to electronic format. To 
avoid use of retrospectively entered routine consultation 
data, we examined routine data recorded only after the 
date the practice began to use full electronic medical 
records. For comorbidities, diagnostic data entered 
retrospectively were considered valid for the purposes of 
identifying a comorbidity (appendix).
We recorded demographic characteristics: sex, age at 
COPD diagnosis, smoking status (recorded within 
12 months of date of COPD diagnosis), location of 
diagnosis (primary or secondary care), lung function 
(forced expiratory volume in 1 s as a percentage of 
predicted [FEV1%], recorded before or up to 10 years after 
COPD diagnosis), and airﬂ ow obstruction grading at 
COPD diagnosis (consistent with UK and 2011 Global 
Initiative for Chronic Obstructive Lung Disease [GOLD] 
airﬂ ow obstruction severity categories: GOLD I=FEV1% 
≥80; GOLD II=FEV1% 50–79; GOLD III=FEV1% 30–49; 
and GOLD IV=FEV1% <30).22 The MRC dyspnoea scale26 
was not routinely recorded across the timeframe analysed 
so it was not included.
We identiﬁ ed missed opportunities for COPD 
diagnosis for each patient. We used three primary care 
measures of missed opportunity. First, lower respiratory 
consultations, deﬁ ned as all consultations coded for 
lower respiratory complaints, including lower respiratory 
tract infections (such as bronchitis, tracheitis, and 
pneumonia, which might need antibiotic treatment), 
non-infective lower respiratory conditions (such as 
asbestosis and chronic respiratory failure), and 
respiratory symptoms (such as breathlessness, hyper-
ventilation, cough, and wheezing). Second, consultations 
for lower respiratory symptoms with a course of 
antibiotic drugs or oral steroids prescribed on the same 
day. And third, chest radiography. We searched 919 lower 
respiratory Read Codes covering symptoms, diagnoses, 
and procedures to identify all possible consultations at 
which the patient would have presented with lower 
respiratory symptoms. Chest radiographs were included 
as a missed opportunity even if they were not done to 
look for COPD speciﬁ cally, because it suggests that the 
patient had symptoms for which the diﬀ erential 
diagnosis could have included COPD.
Missed opportunities during secondary care were 
respiratory-related outpatient and unscheduled hospital 
admissions that did not lead to a coded diagnosis of 
COPD. The 20-year period of time leading up to COPD 
diagnosis was stratiﬁ ed into four bands: 0–5 years, 
6–10 years, 11–15 years, and 16–20 years. To be included in 
the periods 6–10 years, 11–15 years, and 16–20 years, 
patients had to have no less than 10 years, 15 years, 
For the the General Practice 
Research Database see http://
www.cprd.com
For the Optimum Patient Care 
Research Database see http://
www.optimumpatientcare.org/
OPCRD.html
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or 20 years of data, respectively. Patients with less 
than 10 years of data were included in the 0–5 year period.
We also identiﬁ ed recorded COPD exacerbations in the 
2 years after diagnosis. Exacerbations were deﬁ ned as: 
admission to hospital or accident and emergency 
attendance coded for COPD or lower respiratory 
prescribing consultations requiring antibiotic drugs or 
oral steroid treatment on the same day.
The appendix shows the deﬁ nitions we used to 
identify active chronic comorbid conditions. We used 
diagnostic codes present at any time before diagnosis of 
COPD for cardiovascular disease, osteoporosis, 
bronchiectasis, asthma, and diabetes (or diabetes 
treatment ever before COPD diagnosis, irrespective of 
presence of a diabetes diagnostic code). We used recent 
diagnostic codes (ie, within 2 years), or diagnostic codes 
present at any time before diagnosis of COPD and 
active drug management (ie, prescriptions within 
2 years of date of COPD diagnosis) to identify gastro-
oesophageal reﬂ ux disease, allergic rhinitis, chronic 
pain, and depression or anxiety. The use of prescription 
data or diagnostic codes aimed to identify all patients 
who (1) might have had a current comorbidity, whether 
or not it was coded (eg, diabetes and chronic pain); and 
(2) for diseases that have a natural history of active 
and remission phases (eg, gastro-oesophageal reﬂ ux 
disease, allergic rhinitis, and depression), ensured that 
only patients with active disease in the 2 years before 
COPD diagnosis were identiﬁ ed. We selected these 
COPD concordant or related comorbidities on the basis 
of our clinical experience and known pathophysiology 
at the time of the study design because no large 
epi demiological studies of comorbidity were available; 
the subsequent work of Barnett and colleagues27 
suggests that this approach was justiﬁ ed.
Statistical analysis
We assessed trends in missed opportunities for 
diagnosing COPD in both primary and secondary care 
over the 20 years preceding diagnosis. Missed 
opportunities in the 2 years immediately before 
diagnosis were also assessed for change over the 20-year 
period (1990–2009). We evaluated age at diagnosis and 
comorbidities present at the time of COPD diagnosis 
over the same 20-year period. We also assessed frequency 
of missed opportunities and comorbidities by severity of 
airway obstruction and by sex. All analyses were done 
with SPSS (version 18).
We used summary statistics for patient characteristics 
at time of COPD diagnosis. We compared age at 
diagnosis by year of diagnosis and by severity of airway 
obstruction with F tests; age at diagnosis between sexes 
with a t test; and severity of airway obstruction by year of 
diagnosis and sex with χ² tests.
We used a general linear model to investigate the 
eﬀ ects of year of diagnosis, sex, place of diagnosis 
(secondary care or primary care), and practice (treated as 
Figure 1: Study population
*Any of shortacting β2 agonist, longacting β2 agonist, inhaled corticosteroid, 
shortacting anticholinergic, longacting anticholinergic, leukotriene receptor 
antagonist, or theophylline. COPD=chronic obstructive pulmonary disease.
9452 excluded
3978 had COPD diagnosed
before 1990
5474 did not have 
≥12 months of outcome 
data after COPD diagnosis
1 122 787 patients
75 684 diagnosed with 
COPD
66 232 had ﬁrst COPD 
diagnosis after 
1990
38 859 patients with 
COPD analysed
27 373 excluded
1220 age ≤40
12 498 did not have 2 years of
data before and 1 year
of data after diagnosis
13 655 ≤1 COPD prescription in
the year after COPD 
diagnosis*
Total 
(n=38 859)
Patients with 
data for FEV1 
(n=22 821)*
Patients with 
no FEV1 data 
available 
(16 038)
p value
Age at diagnosis (years) <0·0001†
Mean (SD) 67·5 (10·4) 66·3 (10·0) 69·1 (10·7)
Median (IQR) 68 (60–75) 66 (59–74) 70 (62–77)
Range 41–104 41–102 41–104
Sex (n, %) 0·006
Women 18 435 (47%) 10 693 (47%) 7742 (48%)
Men 20 424 (53%) 12 128 (53%) 8296 (52%)
Smoking status (n, %) <0·0001
Data available 28 392 (73%) 19 264 (84%) 9128 (57%)
Non-smoker 2518 (6%) 1894 (8%) 624 (4%)
Current smoker 12 981 (33%) 8468 (37%) 4513 (28%)
Ex-smoker 12 893 (33%) 8902 (39%) 3991 (25%)
Data not available 10 467 (27%) 3557 (16%) 6910 (43%)
Place of diagnosis (n, %) <0·0001
Primary care 38 282 (99%) 22 617 (99%) 15 665 (98%)
Secondary care (inpatient or outpatient) 577 (1%) 204 (1%) 373 (2%)
GOLD FEV1 impairment band* (n, %) NA
FEV1 data‡ available 22 821 (59%) ·· ··
GOLD I (FEV1 ≥80%) 2882 (7%) ·· ··
GOLD II (FEV1 50–79%) 10 347 (27%) ·· ··
GOLD III (FEV1 30–49%) 5669 (15%) ·· ··
GOLD IV (FEV1 <30%) 3923 (10%) ·· ··
FEV1 data‡ unavailable 16 038 (41%) ·· ··
p values are for the comparison of patients with FEV1 data versus those without. COPD=chronic obstructive pulmonary 
disease. NA=not applicable. *FEV1 value recorded ever before or within 10 years of diagnosis. †For diﬀ erence between 
means. ‡FEV1 value or FEV1%. p-value is for diﬀ erence between total cohort and subgroup with valid FEV1 values. 
Table 1: COPD population demographics at time of diagnosis
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a random eﬀ ect to account for potential variations in 
clinical practice and thereby enabling results to be 
generalised across all practices) on age at diagnosis. We 
also included interactions between explanatory variables 
in the model. Interaction terms that were not signiﬁ cant 
were excluded and the model reﬁ tted.
We calculated the number and percentage of patients 
with missed opportunities for diagnosis by year before 
diagnosis (1–20 years before) and in 5-year bands before 
diagnosis. We compared the distributions by sex and 
place of diagnosis (primary or secondary care) with 
χ² tests. We calculated the mean number of missed 
opportunities per patient per year before diagnosis, the 
minimum, and the maximum.
We used generalised linear models to ﬁ nd out how 
missed opportunities to diagnose changed from 1990 to 
2009. The frequency of missed opportunities in primary 
care and in secondary care recorded in the 2 years before 
diagnosis were each modelled as the dependent variable 
in a generalised linear model (with a Poisson distribution 
of errors and a log link) with independent variables of: 
year of diagnosis, age, sex, place of diagnosis (secondary 
care or primary care), and practice (treated as a random 
eﬀ ect to enable results to be generalised across all 
practices). We also included interactions between the 
independent variables in the models. Interaction terms 
that were not signiﬁ cant were excluded and the model 
reﬁ tted. We evaluated prevalence of comorbidities by 
year of COPD diagnosis with a χ² test. For patients with 
data available for FEV1%, we compared the distribution 
of airway obstruction severity by (1) year of diagnosis 
and (2) comorbidity prevalence with a χ² test. We tested 
the association between degree of airway obstruction 
(FEV1%) and frequency of lower respiratory prescribing 
consultations with Spearman’s rank correlation 
coeﬃ  cient. We analysed the prevalence of comorbidity 
by airway obstruction severity with the χ² test.
We used logistic regression to assess the odds of 
multiple COPD exacerbations in the ﬁ rst and second 
years after diagnosis for patients with two or more lower 
respiratory prescribing consultations before diagnosis 
compared with patients with one or no consultations. 
Indicator variables for two or more lower respiratory 
prescribing consultations in the year before diagnosis, 
age, sex, and year of diagnosis were included in the 
model as explanatory variables. We repeated the analysis 
using an indicator for two or more lower respiratory 
prescribing consultations in the 2 years before diagnosis.
This study is registered with ClinicalTrials.gov, number 
NCT01655667.
Role of the funding source
The Department of Health and Research in Real Life 
designed the study, interpreted data, and revised the 
report.  The corresponding author had full access to all of 
the data and the ﬁ nal responsibility to submit for 
publication.
Results
38 859 patients were included in the study from a total of 
1 122 787 patients who had a history of respiratory disease 
(ﬁ gure 1). Average duration of longitudinal data was 
10·4 years (range 3–21 years). All patients had 2 years of 
clinical and treatment data available before diagnosis; 
33 040 of 38 859 (85%) patients had at least 5 years of data.
Table 1 shows the population demographic data. Data 
for smoking history were available for 28 392 of 
38 859 (73%) patients and FEV1% predicted data for 
22 821 of 38 859 (59%) patients. Median duration between 
date of diagnosis and date of recording FEV1% was 
2 months (IQR 0–29 months). Of patients with an FEV1% 
value available at time of COPD diagnosis, a smaller 
proportion of women than of men had evidence of 
0–5 years 
(n=38 859)
6–10 years 
(n=22 286)
11–15 years 
(n=9351)
16–20 years 
(n=1167)
Lower respiratory consultation 32 900 (85%) 12 856 (58%) 3943 (42%) 95 (8%)
Lower respiratory prescribing consultation 26 472 (68%) 10 627 (48%) 3185 (34%) 31 (3%)
Prescribed oral steroids 15 498 (40%) 3869 (17%) 928 (10%) 1 (<1%)
Prescribed antibiotics 21 364 (55%) 8656 (39%) 2544 (27%) 1 (<1%)
Chest radiography 14 675 (38%) 3366 (15%) 648 (7%) 19 (2%)
Outpatient consultation 4237 (11%) 1645 (7%) 364 (4%) 0 (0%)
Admitted to hospital 881 (2%) 220 (1%) 53 (1%) 3 (<1%)
Data are n (%). Shows the number and proportion of patients who had one or more of each event in each 5-year period. 
COPD=chronic obstructive pulmonary disease.
Table 2: Missed opportunities to diagnose COPD in the years preceding diagnosis
Figure 2: Mean frequency of missed opportunities to diagnose COPD
For consultations for lower respiratory symptoms (A), lower respiratory prescribing consultations (B), chest 
radiography (C), and outpatient consultations (D). Too few data were available to present number of admissions to 
hospital. COPD=chronic obstructive pulmonary disease.
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airﬂ ow limitation (appendix). Small but signiﬁ cant 
demographic diﬀ erences were present between the 
22 821 patients with data available for predicted FEV1% 
and those without such data available (table 1). Patients 
with available FEV1 data were 2·8 years (95% CI 2·6–3·1) 
younger (p<0·0001), were more likely to be men (odds 
ratio [OR] 1·06, 95% CI 1·02–1·10; p=0·006), have 
smoking status available (4·10, 3·91–4·30; p<0·0001), be 
current or ex-smokers (0·67, 0·61–0·74; p<0·0001), and 
were more likely to be diagnosed in primary care 
(2·64, 2·22–3·14; p<0·0001). 
During the 20 years preceding diagnosis, opportunities 
to diagnose COPD related to lower respiratory events 
were missed in both primary and secondary care (table 2, 
appendix). Opportunities were missed during all four, 
5-year periods (0–5, 6–10, 11–15, and 16–20 years), with 
many patients having opportunities missed in two or 
more 5-year periods in both primary and secondary care. 
The average number of missed opportunities per patient 
per year also increased leading up to the date of diagnosis 
(ﬁ gure 2). 25 of 379 (6·6%) patients diagnosed in 
secondary care had one or more admissions to hospital 
in the 5 years before diagnosis, compared with 457 of 
38 480 (1·2%) diagnosed in primary care (OR 5·55, 
95% CI 3·67–8·41; p<0·0001).
From 16 years before diagnosis of COPD, and each year 
until diagnosis, female patients had consistently more 
missed opportunities in terms of lower respiratory 
consultations and lower respiratory prescribing 
consultations than did male patients (p<0·0001; data not 
shown). We noted that men were more likely to have a 
chest radiography requested in the year before diagnosis 
than were women (4948/20 424 [24·2%] vs 4019/18 435 
[21·8%]; OR 1·11, 95% CI 1·06–1·16; p<0·0001), women 
were more likely to be admitted to hospital in the 2 years 
before diagnosis than were men (266/18 435 [1·44%] vs 
216/20 424 [1·06%]; OR 1·36, 95% CI 1·14–1·63; p<0·0001), 
but we report no signiﬁ cant diﬀ erence for outpatient 
attendances (398/18 435 [2·2%] women vs 429/20 425 
[2·1%] men; OR 1·03, 95% CI 0·89–1·18; p=0·696).
Table 3 and ﬁ gure 3 show comorbidity prevalence data 
at the time of COPD diagnosis from 1990 to 2009. 
Prevalence of all comorbidities present at COPD 
diagnosis signiﬁ cantly increased over this period, with 
the exception of asthma and bronchiectasis, which had 
small but signiﬁ cant decreases. The highest yearly means 
for active comorbidities were chronic pain (40%), asthma 
(34%), diabetes (18%), depression or anxiety (16%), and 
cardiovascular disease (15%). Presence of one or more 
diagnosed comorbidities at the time of COPD diagnosis 
was associated with less airway obstruction (22 821 patients 
had data for airway obstruction; appendix).
Many opportunities to diagnose COPD were missed in 
the 2 years before diagnosis (appendix) throughout the 
20-year evaluation period. The number of lower 
respiratory prescribing consultations per year signiﬁ cantly 
decreased from 1990 to 2009 (rate ratio 0·982 per year, 
95% CI 0·979–0·985), as did the number of outpatient 
consultations per year (0·917 per year, 95% CI 0·910–0·925; 
table 4). The yearly rate of all lower respiratory 
consultations decreased signiﬁ cantly for patients 
eventually diagnosed in secondary care (rate ratio 0·955 
per year, 95% CI 0·934–0·976) but remained consistent 
for patients diagnosed in primary care (rate ratio 1·000 
per year, 95% CI 0·998–1·003); whereas the number of 
chest radiographs signiﬁ cantly increased with year of 
diagnosis (rate ratio 1·093 per year, 95% CI 1·088–1·097). 
Because of the small numbers, change in frequency of 
admission to hospital over time could not be evaluated. 
For the 22 821 patients with an FEV1% value, the frequency 
of lower respiratory prescribing consultations in the 
5 years before diagnosis was not correlated with airway 
obstruction (r –0·012; p=0·075). Of the 6897 patients who 
had chest radiography in the 2–24 months before 
diagnosis, only 2296 (33%) had evidence of having had 
spirometry (with or without an FEV1% value) in the same 
period.
Figure 3: Prevalence of comorbidity at the time of COPD diagnosis for 
patients diagnosed between 1990 and 2009
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Mean prevalence 
1990–2009 (%)
Prevalence 
in 1990 (%) 
Prevalence 
in 2007 (%) 
Asthma 34% 33% 31%
Bronchiectasis 4% 6% 4%
Cardiovascular disease* 15% 7% 14%
Gastro-oesophageal reﬂ ux disease 7% 1% 7%
Osteoporosis 3% 1% 6%
Diabetes 18% 13% 23%
Sinusitus 3% 0% 5%
Chronic pain 40% 17% 48%
Depression and anxiety 16% 7% 19%
Allergic rhinitis 7% 4% 6%
Because of small numbers of patients in 2008 and 2009, results for these years were inconsistent with the general 
trend over time and therefore results for 2007 are reported here instead. COPD=chronic obstructive pulmonary disease. 
*Heart failure, angina, or myocardial infarction.
Table 3: Prevalence of comorbidities at time of COPD diagnosis
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Median age of the total population at diagnosis fell from 
69 years (IQR 62–76) in 1990, to 67 years (62–77) in 2007. 
However, by contrast with the raw data, the general linear 
model, which included practice as a random eﬀ ect, 
reported a yearly increase in age at diagnosis (table 5). 
Excluding practice from the model reversed the ﬁ ndings in 
line with the raw values. Increasing chronological year of 
diagnosis was associated with an increasing proportion of 
patients with a lesser degree of airﬂ ow obstruction at time 
of COPD diagnosis (appendix) and a higher frequency of 
multiple comorbidities (two, three, or more; appendix).
10 271 of 38 859 (26%) patients had two or more lower 
respiratory prescribing consultations in the year 
preceding diagnosis and data available for 2 years after 
diagnosis. Two or more lower respiratory prescribing 
consultations in the year preceding diagnosis were 
associated with an increased likelihood of having two or 
more exacerbations in the ﬁ rst year after diagnosis 
(OR 3·10, 95% CI 2·95–3·26) and the second year 
after diagnosis (2·73, 95% CI 2·59–2·87). 14  730 of 
38 859 (38%) patients who had two or more lower 
respiratory prescribing consultations in the 2 years 
preceding diagnosis had an increased likelihood of 
having two or more exacerbations in the ﬁ rst year after 
diagnosis (OR 3·16, 95% CI 3·01–3·32) and the second 
year after diagnosis (2·81, 2·67–2·96). 
Discussion
Our ﬁ ndings show that, during the 20 years leading up to 
diagnosis, the proportion of patient consultations in 
primary and secondary care (and the frequency of 
consultations) for lower respiratory symptoms, antibiotic 
and oral steroid prescriptions, and chest radiography 
increased. Indeed, 85% of patients consulted primary 
care for lower respiratory symptoms in the 5 years before 
diagnosis of COPD. This ﬁ nding conﬁ rms that many 
opportunities exist for earlier diagnosis of COPD in the 
course of routine clinical practice in the UK; recognition 
of these opportunities could be incorporated to serve as 
part of a case-ﬁ nding strategy for patients with COPD 
and associated comorbidities (panel).
Women had more missed opportunities in primary 
care, but not in secondary care, than did men. One 
explanation might be that general practitioners are less 
likely to suspect COPD in women than in men. 
However, in this study—as in others—men had more 
severe airway obstruction at time of diagnosis than did 
women.31 Bridevaux and colleagues32 have reported that 
increased weight gain in female but not male patients 
with COPD was associated with rapid fall of FEV1; thus, 
opportunities for early diagnosis and intervention 
including the provision of lifestyle advice are important. 
Contrary to the GOLD guidelines,22 which document 
reduced FEV1 as one of the deﬁ ning parameters for risk 
of exacerbation, we report that the frequency of lower 
respiratory prescribing consultations was not associated 
with degree of airway obstruction (FEV1%), although a 
history of lower respiratory prescribing consultations 
before diagnosis was associated with an increased risk 
of exacerbations after diagnosis. The absence of 
association between frequency of lower respiratory 
prescribing consultations and degree of airway 
obstruction might be a result of selection bias, although 
since the implementation of the Quality Outcome 
Framework in 2005, most patients diagnosed had an 
FEV1% value available. In view of our ﬁ ndings and those 
for the SAPALDIA cohort33 study— which showed an 
association between early symptom presentation and 
progression to COPD—a history of multiple lower 
respiratory prescribing consultations could be a useful 
marker for case-ﬁ nding as well as predicting which 
patients are likely to have frequent exacerbations after 
diagnosis.
Recent COPD policy and practice guidance have aimed 
to improve COPD diagnosis. Over the 20-year study period, 
median age at diagnosis reduced slightly between 1990 
Dependent 
variable
Independent variable Rate ratio per year 
(95% CI)
Lower respiratory 
prescribing 
consultations
Year of diagnosis
Age at diagnosis
Men
Women
0·982 (0·979–0·985)
1·004 (1·002–1·006)
0·992 (0·991–0·994)
Lower respiratory 
consultations
Age at diagnosis
Men diagnosed in secondary care
Men diagnosed in primary care
Women diagnosed in secondary care
Women diagnosed in primary care
Year of diagnosis
Secondary care
Primary care
0·990 (0·980–1·001)
1·004 (1·002–1·006)
0·982 (0·972–0·993)
0·996 (0·994–0·997)
0·955 (0·934–0·976)
1·000 (0·998–1·003)
Chest radiography Year of diagnosis
Age at diagnosis
Diagnosed in secondary care vs primary care (reference)
Men vs women (reference)
1·093 (1·088–1·097)
1·002 (1·001–1·004)
0·73 (0·57–0·94)*
1·10 (1·06–1·14)*
Outpatient visits Year of diagnosis
Age at diagnosis
Men
Women
Diagnosed in secondary care vs primary care (reference)
0·917 (0·910–0·925)
0·998 (0·992–1·004)
0·988 (0·982–0·993)
1·49 (1·06–2·02)*
*Rate ratio (95% CI) not rate ratio per year.
Table 4: General linear model derived rate ratios for missed opportunities
Dependent variable Independent variable Diﬀ erence in age (years)
Age at diagnosis including 
practice as a random 
eﬀ ect
Increase in age per increase in year
Diagnosis in secondary care vs 
primary care
Men vs women
Practice
Sex by practice
0·06 (0·04–0·09)
2·82 (1·77–3·87)
0·35 (0·02–0·68)
Signiﬁ cant (age varies across practices)
Signiﬁ cant (age varies with sex across 
practices)
Age at diagnosis 
excluding practice 
as a random eﬀ ect
Decrease in age per increase in year 
Diagnosis in secondary care vs 
primary care
0·05 (0·03–0·07)
2·15 (1·10–3·20)
Data are mean (95% CI).
Table 5: Mean diﬀ erences in age at diagnosis from general linear model
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and 2007, as did the yearly mean adjusted age at diagnosis 
(excluding practice). However, adjustment for practice (as 
a random eﬀ ect) resulted in a reversal of the trend, with 
the yearly mean adjusted age at diagnosis increasing over 
time. This ﬁ nding suggests that practice policy might have 
signiﬁ cantly aﬀ ected age at diagnosis over the study 
duration. Over the same time period, we also recorded 
reductions in the frequency of lower respiratory events, 
substantial increases in the prevalence of common COPD 
comorbidities, and a reduction in the proportion of 
patients with high airﬂ ow obstruction at diagnosis, which 
is contrary to the accepted notion that patients with many 
comorbidities have severe COPD disease.34 
Analyses using historical primary care datasets are 
limited by the quality of the data. However, treatment 
and consultation data in UK electronic patient records 
are regarded to be of high quality,35–37 with treatment data 
accepted as a reliable proxy of dispensed drugs (in the 
UK, pharmacists are required to dispense drugs that 
physicians prescribe). The diagnosis of COPD in this 
study is based on the presence of a coded diagnosis of 
COPD and at least two prescriptions for COPD treatment 
to indicate initiation and continuation of treatment. We 
did not assess the diﬀ erent phenotypes of COPD. 
Because the dataset draws from a geographically and 
socioeconomically diverse population, we believe that the 
study results are widely applicable to routine clinical 
practice in the UK.
Active long-term comorbid disease was deﬁ ned a priori 
as a recent diagnostic code or as ever having had a 
diagnostic code plus recent treatment for disorders that 
might entail long-term treatment and no re-entry of 
diagnostic coding. We recorded a high prevalence of 
asthma across all COPD severities. A possible cause is 
that many patients receive an initial diagnosis of asthma 
on the basis of their symptoms, which is not updated (to 
asthma resolved) when they are subsequently diagnosed 
with COPD. As diagnostic accuracy improves, asthma 
and COPD phenotypes should be better delineated. 
Using population-based cohorts established in the late 
1980s from the Atherosclerosis Risk in Communities 
Study and the Cardiovascular Health Study, Mannino 
and colleagues34 reported that prevalence of diabetes, 
hypertension, and cardiovascular disease increased with 
increasing airﬂ ow obstruction. By contrast, across almost 
all the comorbidities, we report that a higher prevalence 
of comorbidity was associated with less airway 
obstruction at the time of diagnosis. This ﬁ nding 
suggests that the presence of comorbidities leads to 
earlier COPD diagnosis, because those with comorbidities 
are more likely to visit their family doctor or nurse, 
leading to increased opportunities to identify symptoms 
and a diagnosis. Also there may be increased awareness 
of the risk of COPD in these patients (perhaps driven by 
national targets such as the UK’s Quality and Outcomes 
Framework).38 Conversely, patients with fewer co-
morbidities attended their family doctor less frequently, 
resulting in fewer opportunities for diagnosis and 
therefore fewer chances to implement steps that might 
slow disease progression. This eﬀ ect might have led to 
increased disease progression.
Our data searches showed that recording routine data 
into electronic patient records started around 
15–20 years ago. During the initial years after transition 
from paper to electronic patient records, not all 
consultations were fully coded, limiting the usability of 
the data. The introduction in 2005 of the UK Quality 
and Outcomes Framework, which requires current 
smoking status and a valid FEV1 value to be entered into 
the COPD patient record, has improved the frequency 
of data recording.34 We maximised the FEV1% data 
available by using the nearest recorded FEV1 or FEV1% 
value recorded either before diagnosis or within 10 years 
after diagnosis. Yearly decrease of lung function is 
25–30 mL per year for patients aged 35–40 years, 
increasing to 60 mL per year for those aged 70 years and 
older.39 Thus, the small median duration between the 
date of entry of FEV1 value and date of diagnosis in our 
dataset (2 months, IQR 0–29), suggests that the duration 
over which the FEV1 data were identiﬁ ed did not 
signiﬁ cantly aﬀ ect our ﬁ ndings. If spirometry values 
Panel: Research in context
Systematic review
COPD is increasing in prevalence, yet studies have reported that it is often 
underdiagnosed or misdiagnosed. Strategies to improve COPD diagnosis in primary care, 
including case-ﬁ nding strategies, have been proposed.28 Although episodes of lower 
respiratory symptoms are an indicator of COPD, no studies have assessed whether 
measures of routinely collected resource data for lower respiratory health could be useful 
for identiﬁ cation of at-risk patients. Comorbidities are highly prevalent in COPD.29 Indeed, 
patient-centred management, which includes assessment of current and consideration of 
potential comorbidities, is advocated by Fabbri and colleagues30 on behalf of the American 
Thoracic Society. Yet, whether a patient-centred management approach could lead to 
diagnosis of COPD in patients with an established concordant comorbidity is unknown.
Interpretation
Opportunities to diagnose COPD are being missed in primary and secondary care despite 
the frequency of opportunities increasing, particularly during the 5 years immediately 
before diagnosis. Although we report small improvements in diagnosis of COPD for 
patients diagnosed at a young age, after few lower respiratory infections, and at an early 
stage in the course of disease, many patients were still being diagnosed with severe or very 
severe airway obstruction. Prevalence of concordant comorbidities (diabetes, 
cardiovascular disease, gastro-esophageal reﬂ ux disease, allergic rhinitis, sinusitis, 
depression or anxiety, and chronic pain) at the time of COPD diagnosis have signiﬁ cantly 
increased. The presence of a concordant comorbidity at diagnosis is associated with less 
airway obstruction at time of diagnosis, suggesting that attendance at clinics for the 
comorbidity is raising the possibility of the presence of COPD. COPD should be considered, 
and spirometry done for patients aged 40 years or older and current or ex-smoker, 
previously or currently presenting with lower respiratory tract symptoms in primary care, 
in those referred for chest radiography, or as outpatients for respiratory symptoms. 
Patient-centred management involving the assessment of present and potential 
comorbidities should be implemented to maximise opportunities for diagnosis of COPD, 
consistent with the ﬁ ndings of Barnett and colleagues.27
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were missing, we assumed that patients had spirometry 
done to inform the diagnosis, but results were not 
entered. Although small but signiﬁ cant diﬀ erences for 
age at diagnosis, sex, place of diagnosis, and recording 
of smoking history existed between the FEV1 subgroups 
and the total population, we believe our ﬁ ndings can be 
generalised to the COPD population as a whole. Indeed, 
the greater characterisation of the FEV1 subgroup is 
consistent with management of chronic disease moving 
to a primary care setting and the implementation of 
Quality and Outcomes Framework targets for recording 
smoking status and FEV1. However, questions remain 
about the overall quality of spirometry in primary care, 
and therefore the accuracy of any results.
It might be easier to identify those at risk of COPD by 
auditing a practice’s patient records systematically rather 
than attempting to do so opportunistically during a 
consultation. Time pressure can lead to short 
consultations and reduced continuity of care. Case-
ﬁ nding strategies have been proposed as a mechanism 
for identifying high-risk patients. To date, these strategies 
have focused on patients with appropriate symptoms and 
risk factors including smoking,19,20,40 but have not included 
the number of lower respiratory consultations or chest 
radiographs (discrete clinical episodes). Screening 
asymptomatic patients for COPD with spirometry does 
not seem justiﬁ ed by current evidence20 and is less useful 
in young people, for whom the pre-test probability of 
COPD is low.41 Prospective case-ﬁ nding studies that 
include use of health-care resources are needed to 
establish how our ﬁ ndings can be used in routine 
primary care to help identify patients with COPD as early 
as possible. Such studies would require establishing 
background levels of use of respiratory health-care 
resources in the short term and long term for the healthy 
non-COPD population. We noted that the yearly 
frequency of missed opportunities increased in the 
5 years immediately before diagnosis, therefore a 5-year 
review window of discrete clinical episodes might be 
appropriate for case-ﬁ nding. Indeed, a 5-year window 
would avoid diﬃ  culties such as availability of data and 
changing awareness of COPD and investigations (for 
example following the implementation of the Quality 
and Outcomes Framework).
Decline in lung function seems to be steepest in the 
early stages of disease,42 indicating that opportunities to 
diagnose COPD earlier should be taken as early as 
possible. Our data suggest that: (1) although recurrent 
respiratory infections should always be assessed in their 
own right and treated accordingly, the possible presence 
of COPD should also be considered; (2) patients who 
smoke (current or past), are aged 40 years or older, 
presenting with lower respiratory symptoms requiring a 
prescription should be recalled after 6 weeks for 
spirometry to detect COPD; and (3) COPD symptoms 
should also be sought in patients who do or have smoked, 
are aged 40 years or older, and are attending clinics for 
COPD concordant comorbidities with screening (hand-
held or similar) spirometry done as appropriate.5 The 
diagnosis of COPD should include clinical assessment 
and stratiﬁ cation and be conﬁ rmed by post-
bronchodilator spirometry done by trained staﬀ  using 
appropriate devices.43 Although most general practices in 
the UK have a spirometer, our data conﬁ rm that barriers 
to eﬀ ective spirometric evaluation exist, probably in the 
form of time pressures, lack of appropriate training, and 
low conﬁ dence in interpretation of results.44,45 Although 
chest radiography might be needed to rule out cancer or 
tuberculosis, requesting a chest radiograph indicates that 
an opportunity to consider COPD might have been 
missed. In such cases, spirometry could have been 
ordered as well as chest radiography.
We noted that patients who have had recurrent lower 
respiratory prescribing consultations before COPD 
diagnosis are at a greater risk of future exacerbations. 
This ﬁ nding is consistent with the frequent exacerbator 
phenotype described by Hurst and colleages.46 Because 
people who have frequent exacerbations are liable to 
rapid decline in lung function and low quality of life,15,17 
they have much to gain from early detection.42 Indeed, 
our results suggest that patients tended to have moderate-
to-severe disease at the point of diagnosis, thereby 
minimising the potential beneﬁ t that starting treatment 
could provide in terms of delayed disease progression. 
Prospective studies are necessary to conﬁ rm the beneﬁ t, 
if any, of early detection and management of COPD in 
primary care, based on the ﬁ ndings of our study.
What improvements can be made? The situation in the 
UK—where these data were recorded—has steadily 
improved over the past 20 years. This improvement 
might be partly related to resource allocation to encourage 
use of diagnostic spirometry and recent policies of the 
Department of Health.5,6 An important priority is 
education of primary care nurses and doctors to be aware 
of the possibility of COPD in people presenting with risk 
factors (including comorbidity) and respiratory 
symptoms, and to undertake quality spirometry as an 
early investigation. Proposals to address these priorities 
have included incentivisation of primary care as a means 
of obtaining access to quality spirometry,43 coupled with 
knowledge and skills about disease management and an 
enhanced yearly structured review. Collaboration with 
community workers such as respiratory nurses, smoking 
cessation counsellors, and public health workers who 
provide dietary and exercise advice has the potential to 
improve clinical outcomes while reducing hospital 
admissions and treatment costs, as evidenced by the 
Finnish 10-year COPD Programme.47 Because the 
Programme showed no improvement in the number 
of patients diagnosed with COPD, integration of a 
case-ﬁ nding strategy—including analysis of routinely 
collected data—to identify patients at risk of COPD and 
who might beneﬁ t from further assessment could lead to 
further improvements.
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We suggest that a case-ﬁ nding approach should be 
modiﬁ ed to include: all patients older than 40 years with 
a diagnosis of asthma and who currently smoke; all 
smokers older than 40 years who have a lower respiratory 
prescribing event; and follow-up of existing 
recommendations for smokers aged older than 40 years 
with any respiratory symptoms, especially if they are 
male. Although we are unable to discern the principal 
drivers responsible for the small improvements in COPD 
diagnosis over the 20-year study period, our study 
suggests that patient outcomes could be improved when 
a person-centred approach to disease management is 
taken, including both related or concordant and unrelated 
disconcordant comorbidities. Decision support software 
could be used to automatically generate prompts for 
clinicians on possible next steps for patients deemed at 
risk. The substantial ﬁ nancial costs of failing to diagnose 
and treat COPD until a later stage would probably 
outweigh the costs of implementing this approach. 
Understanding historical patterns of respiratory 
symptoms, treatments, and test results, comorbidities 
and health-care resource use in patient-centred primary 
care such as we propose relies on a doctor having access 
to all current and past records and information. For 
health-care systems outside of the UK that are less 
focused on primary care—eg, in the USA—implemention 
of mechanisms to enable clinical information to be 
shared with family doctors is essential if diagnosis of 
COPD is to improve.
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